{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:13:00Z","timestamp":1787008380745,"version":"build-2736575974"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The purpose of this therapy update is to highlight new clinical studies comparing ceftobiprole to current therapies and provide evidence for its suggested role in therapeutic management of selected infectious diseases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Antimicrobial resistance continues to be a global health problem, and newer targeted antimicrobials are necessary to combat increasing rates of problematic infections. More specifically, targeted antimicrobials against methicillin-resistant Staphylococcus aureus are needed. Ceftobiprole has been marketed internationally for the treatment of complicated skin and skin structure infections, community-acquired pneumonia, and hospital-acquired pneumonia. While Food and Drug Administration approval was previously pursued for its use in acute bacterial skin and skin structure infections in the US, the Food and Drug Administration issued a complete response letter determining that study data were unreliable and recommended completion of additional studies. In April 2024, ceftobiprole was granted approval for 3 indications in the US based on updated clinical study data. Ceftobiprole is the second fifth-generation cephalosporin to be developed and approved for clinical use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Ceftobiprole has been shown to be safe and effective in treating specific infectious diseases such as bloodstream infections, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia. Its use should be considered when targeting infections caused by methicillin-resistant S. aureus where other therapeutic options may be limited. However, additional real-world data on the efficacy of ceftobiprole should be continually monitored as experience in the US increases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajhp\/zxaf006","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T07:14:44Z","timestamp":1737530084000},"page":"e489-e497","source":"Crossref","is-referenced-by-count":7,"title":["Ceftobiprole: A therapeutic update"],"prefix":"10.1093","volume":"82","author":[{"given":"Emily M","family":"Hitt","sequence":"first","affiliation":[{"name":"Pharmacotherapy Department, Washington State University College of Pharmacy and Pharmaceutical Sciences , Spokane, WA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana R","family":"Bowers","sequence":"additional","affiliation":[{"name":"Pharmacotherapy Department, Washington State University College of Pharmacy and Pharmaceutical Sciences , Yakima, WA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"issue":"10325","key":"2025052400121510900_CIT0001","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Antimicrobial Resistance Collaborators","year":"2022","journal-title":"Lancet"},{"key":"2025052400121510900_CIT0002","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1146\/annurev-biochem-060614-034516","article-title":"Mechanisms of methicillin resistance in Staphylococcus aureus","volume":"84","author":"Peacock","year":"2015","journal-title":"Annu Rev Biochem"},{"key":"2025052400121510900_CIT0003","author":"Fierce Biotech","year":"2009"},{"key":"2025052400121510900_CIT0004","author":"Basilea Pharmaceutica","year":"2013","journal-title":"Basilea\u2019s antibiotic ceftobiprole obtains regulatory approval in Europe for pneumonia"},{"issue":"3","key":"2025052400121510900_CIT0005","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.ijantimicag.2011.11.005","article-title":"A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation","volume":"39","author":"Nicholson","year":"2012","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"2025052400121510900_CIT0006","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1093\/cid\/ciu219","article-title":"A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia","volume":"59","author":"Awad","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2025052400121510900_CIT0007","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1128\/AAC.00551-07","article-title":"Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria","volume":"52","author":"Noel","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"2025052400121510900_CIT0008","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1086\/526527","article-title":"A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections","volume":"46","author":"Noel","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2025052400121510900_CIT0009","author":"Fierce Biotech","year":"2010"},{"key":"2025052400121510900_CIT0010","author":"Food and Drug Administration","year":"2024"},{"key":"2025052400121510900_CIT0011","author":"Zevtera"},{"issue":"4","key":"2025052400121510900_CIT0012","doi-asserted-by":"publisher","first-page":"245","DOI":"10.2165\/00128071-200809040-00004","article-title":"Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin","volume":"9","author":"Zhanel","year":"2008","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"2025052400121510900_CIT0013","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.ijantimicag.2013.11.005","article-title":"Activity of ceftobiprole against methicillin-resistant Staphylococcus aureus strains with reduced susceptibility to daptomycin, linezolid or vancomycin, and strains with defined SCCmec types","volume":"43","author":"Farrell","year":"2014","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"2025052400121510900_CIT0014","doi-asserted-by":"publisher","first-page":"e01566","DOI":"10.1128\/aac.01566-18","article-title":"Ceftobiprole activity against gram-positive and -negative pathogens collected from the United States in 2006 and 2016","volume":"63","author":"Pfaller","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"2025052400121510900_CIT0015","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.1128\/AAC.00336-08","article-title":"In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections","volume":"52","author":"Amsler","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"2025052400121510900_CIT0016","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/1120009X.2024.2316539","article-title":"Evaluation of in vitro activity of ceftaroline, ceftobiprole and their combination with trimethoprim\/sulfamethoxazole against MRSA isolates: a two center study","volume":"36","author":"Mirza","year":"2024","journal-title":"J Chemother"},{"issue":"15","key":"2025052400121510900_CIT0017","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1056\/NEJMoa2300220","article-title":"Ceftobiprole for treatment of complicated Staphylococcus aureus bacteremia","volume":"389","author":"Holland","year":"2023","journal-title":"N Engl J Med"},{"key":"2025052400121510900_CIT0018","author":"Basilea Pharmaceutica","year":"2023"},{"issue":"7","key":"2025052400121510900_CIT0019","doi-asserted-by":"publisher","first-page":"e1507","DOI":"10.1093\/cid\/ciaa974","article-title":"Ceftobiprole compared with vancomycin plus aztreonam in the treatment of acute bacterial skin and skin structure infections: results of a phase 3, randomized, double-blind trial (TARGET)","volume":"73","author":"Overcash","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2025052400121510900_CIT0020","volume-title":"Ceftobiprole in the treatment of patients with acute bacterial skin and skin structure infections","author":"Basilea Pharmaceutica","year":"2023"},{"key":"2025052400121510900_CIT0021","volume-title":"Ceftobiprole in the treatment of patients with community-acquired pneumonia","author":"Basilea Pharmaceutica","year":"2012"},{"issue":"6","key":"2025052400121510900_CIT0022","doi-asserted-by":"publisher","first-page":"e222","DOI":"10.1097\/INF.0000000000003077","article-title":"A phase 3, randomized, investigator-blinded trial comparing ceftobiprole with a standard-of-care cephalosporin, with or without vancomycin, for the treatment of pneumonia in pediatric patients","volume":"40","author":"Bosheva","year":"2021","journal-title":"Pediatr Infect Dis J"},{"key":"2025052400121510900_CIT0023","author":"Basilea Pharmaceutica","year":"2023"},{"issue":"1","key":"2025052400121510900_CIT0024","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1080\/14740338.2023.2299377","article-title":"Safety and effectiveness of fifth generation cephalosporins for the treatment of methicillin-resistant Staphylococcus aureus bloodstream infections: a narrative review exploring past, present, and future","volume":"23","author":"Bavaro","year":"2024","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"2025052400121510900_CIT0025","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"5","key":"2025052400121510900_CIT0026","doi-asserted-by":"publisher","first-page":"e02483","DOI":"10.1128\/AAC.02483-18","article-title":"Clinical data on daptomycin plus ceftaroline versus standard of care monotherapy in the treatment of methicillin-resistant Staphylococcus aureus bacteremia","volume":"63","author":"Geriak","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2025052400121510900_CIT0027","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jgar.2019.07.020","article-title":"Ceftobiprole for the treatment of infective endocarditis: a case series","volume":"20","author":"Tascini","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"key":"2025052400121510900_CIT0028","author":"Teflaro"},{"issue":"4","key":"2025052400121510900_CIT0029","doi-asserted-by":"publisher","first-page":"725","DOI":"10.3390\/microorganisms12040725","article-title":"Real-world experience of ceftobiprole for community- and hospital-acquired pneumonia from a stewardship perspective","volume":"12","author":"Corcione","year":"2024","journal-title":"Microorganisms"},{"key":"2025052400121510900_CIT0030","article-title":"Ceftobiprole for MRSA bacteremia: coming to America","author":"Sakoulas","year":"2023","journal-title":"NEJM Journal Watch"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxaf006\/61591713\/zxaf006.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/82\/11\/e489\/61591713\/zxaf006.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/82\/11\/e489\/61591713\/zxaf006.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T00:12:23Z","timestamp":1748045543000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/82\/11\/e489\/7976913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,23]]},"references-count":30,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,1,23]]},"published-print":{"date-parts":[[2025,5,23]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxaf006","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6,1]]},"published":{"date-parts":[[2025,1,23]]}}}